The envelope glycoprotein trimer (Env) on the surface of HIV-1 recognizes CD4+ T cells and
mediates viral entry. During this process, Env undergoes substantial conformational …

A central goal of HIV-1 vaccine research is the elicitation of antibodies capable of
neutralizing diverse primary isolates of HIV-1. Here we show that focusing the immune …

Summary The HIV-1-envelope (Env) trimer is covered by a glycan shield of∼ 90 N-linked
oligosaccharides, which comprises roughly half its mass and is a key component of HIV …

The development of stabilized recombinant HIV envelope trimers that mimic the virion
surface molecule has increased enthusiasm for a neutralizing antibody (nAb)-based HIV …

Antibody responses to the HIV-1 envelope glycoproteins can be classified into three groups.
Binding but non-neutralizing responses are directed to epitopes that are expressed on …

The HIV-1 envelope glycoprotein (Env) trimer contains the receptor binding sites and
membrane fusion machinery that introduce the viral genome into the host cell. As the only …

Antibodies serve as critical barriers to viral infection. Humoral immunity to a virus is achieved
through the dual role of antibodies in communicating the presence of invading pathogens in …

Enabled by new approaches for rapid identification and selection of human monoclonal
antibodies, atomic-level structural information for viral surface proteins, and capacity for …

A major goal of HIV-1 vaccine research is the design of immunogens capable of inducing
broadly neutralizing antibodies (bnAbs) that bind to the viral envelope glycoprotein (Env) …

HIV-1 entry into CD4+ target cells is mediated by cleaved envelope glycoprotein (Env)
trimers that have been challenging to characterize structurally. Here, we describe the crystal …